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How many of the talks and posters presented
at the 6th Conference on Retroviruses and
Opportunistic Infections dealt directly with pris-
ons? Very few! However, many of the presen-
tations reported on new drugs and described
new insights in the immunopathogenesis of
HIV, both topics that are relevant to the man-
agement of HIV-infected patients in correc-
tions. 
The two predominant conference themes
were "this is the era of drug resistance" and
"improved T cell function due to HAART has
not led to the eradication of the virus." Despite
the lack of landmark changes in antiretroviral
therapy, the good news is that for those who
have access to them, current therapies contin-
ue to work.
• Origin of HIV
Researchers from the University of Alabama
opened the conference with a report on the
origin of HIV-1. New evidence suggests that
HIV is derived from human contact with chim-
panzees in West Africa, who are infected with
a strain of retrovirus similar to HIV. This pres-
entation was the first to demonstrate homolo-
gy in the virus from chimpanzees, geographic
endemnicity and a plausible mechanism of
transmission from animal to human through
the chimpanzee meat trade.
• Era of Drug Resistant HIV
Dr. Stefano Vella presented a discussion of
"Antiretroviral Therapy in Adults," which
focused on the emergence of resistance and
salvage therapy.  This reflected a growing con-
cern among HIV providers about treating drug-
resistant HIV. Dr. Vella reviewed retrospective
studies of the genotyping and phenotyping
assays that demonstrated the value of these
new tools in the management of HIV resist-
ance. Adding a cautionary note, he suggested
that prospective clinical studies of genotyping
and phenotyping will be required before we
can determine whether clinicians can effec-
tively use these tools to improve patient care.
Notably, he warned against over-reliance on
genotyping and phenotyping. This is because
a viral provirus that is integrated into host DNA
in latently infected cells may be a source of
"archived" resistance to treatment, which may
not be detected by these techniques (Abstract
L1).
Others presented additional data on 153
patients who failed a protease containing reg-
imen. They were randomized to management
using either Genotypic Antiretroviral
Resistance Testing (GART) or standard of
care using routine clinical history. Patients ran-
domized to GART were two-times more likely
to become non-detectable than those whose
management relied on routine clinical history
(50% vs. 23% in the GART vs. Non-GART
treatment arms). It appears that use of viral
resistance testing will soon become part of
standard clinical practice once standardization
has been achieved (Abstract LB8).
In other words, those of us providing clinical
care to HIV-infected inmates will need to learn
the proper use of these assays. GART will
soon be part of the standard of care, however
this will not supplant the need to elicit an accu-
rate and detailed medication history from our
patients. GART will complement our clinical
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HEPP News, a forum for correctional
problem solving, evolved out of ongoing dis-
cussions among HIV specialists based at the
Brown University AIDS Program about the
need for HIV updates designed for practition-
ers in the correctional setting. The board of
editors includes national and regional correc-
tional professionals, selected on the basis of
their experience with HIV care in the correc-
tional environment and their familiarity with
current HIV treatment. HEPP News targets
correctional administrators and HIV/AIDS
care providers including physicians, nurses,
outreach workers and case managers.
Published monthly and distributed by fax,
HEPP News provides up-to-the-moment
information on HIV treatment, efficient
approaches to administering such treat-
ments in the correctional environment,
national and international news related to
HIV in prisons and jails, and correctional
trends that impact HIV treatment. Continuing
Medical Education credits are provided by
the Brown University Office of Continuing
Medical Education to physicians who accu-
rately respond to the questions on the last
page of the newsletter; please see last page
for details.
The editorial board and contributors to
HEPP News are well aware of the critical role
prisons and jails play in the treatment and
prevention of HIV. The goal of HEPP News is
to provide reports of effective and cost-con-
scious HIV care that can truly be implement-
ed within the correctional environment. We
hope this newsletter achieves that goal.
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Dear colleagues and friends,
The evolution of HIV treatment these days seems to occur faster than Darwin could have transcribed it. With each new medical con-
ference, management of HIV becomes more interesting, complex and challenging. In this issue, my colleague and co-editor Anne De
Groot M.D. summarizes the most salient components of new HIV research from the 6th Conference on Retroviruses and Opportunistic
Infections, held in Chicago in early February. 
The most disappointing conference news was that mathematical models now estimate that HIV eradication will take as many as 23
years, using existing HAART regimens. The good news, however, is that for those who take the medication, HAART remains effective
and durable. Moreover, scientists are now exploring ways to purge HIV from latent reservoirs using cytokines such as Interleukin-2 and
removing excess viral particles using plasma apheresis. Though some of the most stimulating science in the area of HIV immunopatho-
genesis does not have direct clinical applicability now, it was only a few short years ago when quantification of HIV (viral load determi-
nations), development of protease inhibitors and the mathematical modeling of HIV replication and eradication seemed theoretical. 
In this month's issue of HEPP News we also provide some preliminary thoughts on the use of abacavir (ABC) in corrections. Many
physicians fear its use in a correctional setting because of the potential for Abacavir Hypersensitivity Syndrome.  This consideration,
however, must be balanced with its outstanding potency. We recommend training all correctional health staff about this problem, espe-
cially those who provide direct clinical care. This month's HIV 101 and HEPPigram further explore the use of abacavir and provide assis-
tance with the diagnosis and management of this syndrome.
Lastly, our Ask the Experts deals with a commonly encountered problem in the correctional setting: patients who have received sequen-
tial monotherapy and may have multi-drug resistant HIV. These are tough and challenging cases and require the knowledge of an expe-
rienced HIV specialist. Moreover, it points out to us that the era of genotypic testing is upon us.  Future issues of HEPP News will help
elucidate the maze of genotypic and phenotypic antiretroviral resistance testing. After reading this issue, readers should understand
how to manage abacavir hypersensitivity, monitor viral load and know the latest updates about HIV antiretroviral development.
Next month we'll continue our update on the Chicago Retrovirus Conference with reports on HIV care utilization, new information on
gender and viral load, insights on the changing epidemiology of HIV and the impact of these reports on HIV care in the correctional set-
ting. In the meantime, please take a moment to write to us and tell us how our content and focus work for you.
Sincerely,
Frederick L. Altice, M.D.
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history to optimize therapy for HIV-infected
patients.
• New Drugs, New Combinations
A number of speakers presented new
approaches to HIV treatment that are in
development. Fusion inhibitors are an excit-
ing new product of basic research on the
mechanics of HIV-1 fusion into T cells.
Drugs that fall in this new class include
chemokine receptor blockers and nucleo-
capsid inhibitors. One such drug, developed
by Triangel Pharmaceuticals, is in phase I tri-
als. In vitrostudies of this drug were pre-
sented, showing that the new drug reduces
the ability of the virus to infect new target
cells (Abstract 616). Other similar drugs
were presented in a session devoted to HIV
treatment. This type of entry-blocking drug is
unlikely to supplant current therapies, how-
ever it may be complementary once patients
have been adequately suppressed using
existing or new antiretrovirals.
One notable new concept was "single class
triple therapy," also known as protease-spar-
ing HAART. Three nucleoside reverse tran-
scriptase inhibitors (NRTIs) are used instead
of a protease - or non-nucleoside reverse
transcriptase inhibitor (NNRTI) - inclusive
regimen to treat HIV. This approach limits a
patient's exposure to more than one class of
HIV agents, thus reserving other agents for
later (hence the term protease-sparing). A
French group reported on the combination of
D4T/DDI/3TC vs. D4T/DDI/Nevirapine and
D4T/DDI/Indinavir. The regimens were
essentially equivalent in patients with early
HIV disease (Abstract 18). In another study,
patients administered AZT/3TC/ABC sup-
pressed their viral loads equally as well at 24
weeks as those on standard combination
regimen, AZT/3TC/Indinavir (For more infor-
mation on abacavir (ABC), see HIV 101.).
The study's limitation is that insufficient data
were available for patients with high viral
loads, and until such are available, the use
of ABC as part of a triple nucleoside ana-
logue combination should be initiated with
caution for those with high viral loads or
more advanced HIV disease.
The conference also included interesting
new pharmacokinetic data on the use of the
combination of indinavir with ritonavir. The
use of 100mg of ritonavir combined with
800mg of indinavir administered twice daily
led to an excellent pharmacokinetic profile
that was not affected by the administration of
food. Current clinical studies will evaluate
the efficacy of this combination versus riton-
avir 400mg with indinavir 800mg in twice
daily regimens. These dosing regimens are
good news for corrections.
Safety and efficacy data were presented on
two new protease inhibitors, amprenavir and
ABT378 combined with RTV. Both had
excellent safety and tolerability profiles
(amprenavir is now available through com-
passionate use protocols). In a dosing study
of ritonavir with ABT378 (in combination with
D4T+3TC among antiretroviral naive
patients), 93% achieved a VL<400
copies/mL among a group of patients with a
mean baseline CD4 of 400 and VL of
100,000 copies/mL (Abstract 15). 
Also highlighted was a potent, second gen-
eration protease inhibitor (AG1776), in
development by Agouron Pharmaceuticals,
that has excellent in vivoactivity against
many high level resistant strains of HIV with
multiple mutations to existing protease
inhibitors (Abstract 11).  Agouron and
DuPont Pharma presented data regarding
three different second generation NNRTIs:
DMP 961, DMP 963 (Abstract 13) and
AG1549 (Abstract 12). These agents had
excellent bioavailability and antiviral activity.
HIV-1 isolates resistant to current NNRTIs
were sensitive to these new agents. The
number of mutations associated with the
development of resistance was correlated
with cross-resistance to these new agents.
Again this supports the need to change
treatment early when resistance is first
detected.  
• HIV Eradication Pushed Into the Future
Several speakers made reference to new
HIV eradication time estimates. According to
current estimates, based on our new under-
standing of latent reservoirs of HIV, the time
it will take to eradicate HIV with HAART has
increased from 18 months to 23 years.
Clearly, more intensive approaches to treat-
ment are required. Hope, however, should
not be forsaken, provided these reassur-
ances: 1) the total size of the HIV reservoir
after HAART is thought to be small; 2) the
latent reservoir may contain drug sensitive
virus if treatment is initiated early and sup-
pression of viral load is rapid; and 3) it is pos-
sible that additional decay in infection may
become evident later with more potent anti-
retroviral regimens. Furthermore, new meth-
ods of activating and deleting latent virus
using immunomodulators such as IL-2
demonstrate early success among patients
with undetectable virus. Finally, as in the
case of latent tuberculosis infection, elimina-
tion may not be totally necessary if immune
control is adequate. 
The relevance of these discussions to cor-
rectional HIV care are clear: we need to
enable our patients to adapt to a lifetime of
a tiretroviral medication and select treat-
ment regimens that are highly effective from
the outset and that patients can adhere to.
By meeting these goals, we will have
patients who are living longer and are eligi-
ble for more aggressive therapeutic options
in the future.
• Adherence
Adherence remains the cornerstone of effec-
tive antiretroviral therapy both for clinical tri-
als and for clinical efficacy.  It was demon-
strated that adherence can be outstanding
even among homeless patients. Much of the
presented science described methods to
measure adherence. While electronic
devices were useful in monitoring adherence
- although once thought to be the gold stan-
dard - they can be problematic. The bottom
line is: develop effective ways for patients in
corrections to have easy medication access
and teach them effective mechanisms for
taking pills. The pharmaceutical industry still
has a long way to go in developing more
user-friendly regimens for corrections. 
• Effect of HAART on Immune Response
Several abstracts presented data on the
r covery of effective T lymphocyte respons-
es among patients with advanced HIV who
achieved  virologic success using HAART.
Although patients successfully responding to
HAART may not always redevelop T lym-
phocyte responses to HIV, several studies
demonstrated renewed responses to CMV,
toxoplasmosis and MAC as well as other
neo-antigens. Poor restoration of these
responses was correlated with risk for
relapse of opportunistic infections and/or
new opportunistic infections (OI) among at-
risk patients treated with HAART. These data
suggest that for some patients, prophylaxis
may be stopped, but we do not yet have
access to the types of tools that would assist
us with these difficult decisions (Abstract
453-7).
The timing of HAART initiation appeared to
be a determinant of the recovery of respons-
es to HIV antigens. Late treatment had some
effect, but recovery of anti-HIV and anti-OI
immune responses was less complete than
among patients who were treated with effec-
tive antiretroviral therapy at earlier stages.
More than one presenter made the analogy
that "holes in the T cell repertoire" were more
difficult to fill in with new, effective T cell
responses the longer one delayed initiation
of HAART (Abstract 329).
The 6th Conference on Retroviruses and Opportunistic Infections
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• Intermittent Therapy: Route to Remission?
The case of the Berlin patient was presented in a poster (Abstract
351) along with a few other cases of "controlled HIV infection." Few
adults, with the exception of this example have achieved complete
viral suppression with the administration of HAART.  The general
consensus among participants was that the type of interrupted
HAART combined with immune stimulation (due to acute Hepatitis A
infection) that put the Berlin patient into apparent remission is not
easy to replicate in other patients. Interrupted therapy will require
intensive study before it can be determined that this approach will
enable some patients to completely discontinue treatment. Patients
who are interested in this approach should be referred to "centers of
excellence." Those of us in corrections do not have enough data to
support such an approach.
• What Innovations Do We Need Now? 
Looking toward the future of antiretroviral therapy, many speakers
emphasized the need for new drugs with better resistance profiles
and suggested that we initiate therapy with more potent regimens.
Cost-intensive genotyping/phenotyping assays may need to be
implemented more frequently as more patients fail their first and sec-
ond lines of therapy. Studies demonstrating the prospective efficacy
of these tools are needed. 
HIV treatment is becoming more complicated with the emergence of
resistance and the addition of new treatment regimens. The implica-
tion for corrections is that the management of HIV-infected individu-
als by experienced providers, and careful monitoring of patient
adh r nce, is important if we want to pre-empt the need for greater
reliance on cost-intensive assays. 
• Looking Beyond the Borders
Dr. Vella said in his closing remark that most of his recommendations
ddressed only 10% of the global population, and that the remaining
90% of people in the world who have no access to treatment should
b  considered.  To place the problem of access to HIV care in a
greater context, he quoted HIV expert Paul Volberding, who said
"inequitable distribution of medical resources is not unique to HIV
infection. Improving health care access is a challenge that extends
beyond that of the HIV epidemic." Dr. Vella need not look much far-
ther than the closest jail or prison. Parallels between health care
access problems in the developing world and our patients' access to
HIV care prior to incarceration are self-evident.
Abstracts available on the web at http://www.retroconference.org/99/ 
*Anne De Groot, M.D., Consultant: Agouron, Bristol-Myers Squbb; Speaker’s
Bureau: Agouron, Bristol-Myers Squbb, Glaxo Wellcome.
The 6th Conference on Retroviruses and Opportunistic Infections
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HEPPigram
A feature of HEPPNews providing concise solutions to correctional HIV-related problems
Management of the Abacavir Hypersensitivity Syndrome (AHS)
1. Counsel patients about the risk and symptoms of this syndrome prior to starting therapy. Consider Abacavir Hypersensitivity
Syndrome (AHS) if the patient is within six weeks of initiating abacavir (ABC) and has a skin rash or two or more of the follow-
ing sets of symptoms that persist and progress beyond 72 to 96 hours:
• fever
• nausea, vomiting, diarrhea or abdominal pain
• myalgias, severe fatigue or malaise
2. Make sure patients are instructed to contact medical staff immediately if symptoms occur within the first six weeks of starting
ABC. Also counsel them NOT to discontinue medications themselves. Doing so would confuse later decision-making.
3. If symptoms develop, evaluate the patient immediately. Evaluation should include blood pressure, examination for rash, chem-
istry profile and CBC. Symptoms may be indistinguishable from a viral syndrome, however they usually do not include respira-
tory complaints. 
4. Arrange to see the patient DAILY for the next 72 hours after symptoms begin. In some cases, admission to the medical infirmary
may be indicated. Do NOT discontinue ABC at this time. If nausea or vomiting is an important component of the patient's symp-
toms, prescribe antiemetics to ensure that the patient can continue to take his/her medication.
5. If the patient has a viral syndrome, the symptoms should abate within 72 to 96 hours. If the symptoms progress or do not remit,
AHS should be considered at that point and the ABC should be stopped. The AHS should not be life threatening if diagnosed
early.
6. If it is decided after waiting the prescribed amount of time that the patient does have the AHS (occurs in 3%-5% of patients),
ABC should be discontinued. The symptoms will abate within 24 to 48 hours.
7. Once the AHS is diagnosed or suspected and medications have been discontinued, NEVER rechallenge the patient with ABC.
Make sure the chart is marked as such and that the patient is counseled to never take ABC again.
8. It is important NOT to stop ABC when symptoms first appear without further investigation as described above, as they are indis-
tinguishable from a viral syndrome. Because AHS is not dangerous if detected early, clinicians have the opportunity to follow the
patient and determine if the patient's symptoms disappear. If, on the other hand, ABC is stopped before confirmation of AHS, it
could preclude the use of a truly potent antiretroviral that the patient might need in the future. Unfortunately, if ABC is stopped
(because of presumed but unconfirmed ASH) it can never be used again.
9. Please note that patients who stop ABC for OTHER reasons (e.g. non-adherence), CAN be restarted on ABC. 

A s k  T h e  E x p e r t s
W h a t  W o u l d  Y o u  D o ?
Expert 1:  David Thomas, M.D.
Medical Director, Florida Department of Corrections, Tallahassee, FL
Consultant: Agouron, Bristol-Myers Squibb;
Speaker’s Bureau: Agouron, Bristol-Myers Squibb.
Unfortunately, this case is common in the prison setting and involves
sequential monotherapy that, as we have learned, is an undesirable treat-
ment strategy. I would not treat this patient without first obtaining a geno-
typic antiretroviral resistance test. Patients may fail therapy because of
development of resistance, non-adherence, malabsorption or pharmacoki-
netic interactions. For four years he was on monotherapy with either AZT
or D4T. For his fifth year, he was placed on progressive monotherapy with
either 3TC (added to AZT) or a protease inhibitor. 
It is clear that the progressive monotherapy use of indinavir in April
1996, an extremely commonplace practice then, led to virologic failure
despite an impressive T cell response - this VL and CD4 paradox is a
recent phenomena of intense interest. The interaction with food is proba-
bly a red herring.  However, if inadequate drug bioavailability occurred,
virological failure has been reported and is not related to the development
of genotypic mutations.
Having been on all classes of existing drugs in 1997, genotyping is
essential. He is likely to have developed the M184V mutation associated
with 3TC resistance. If he has this mutation without other associated NRTI
mutations, there would be a 4-fold decrease in the efficacy of abacavir,
which could then be used. If other NRTI mutations exist, there would be
expected little or no response to ABC. Alternatively, the use of adefovir, a
nucleotide analogue RTI available by compassionate use, is likely to
achieve a 1.0 log reduction in the presence of the M184V mutation. 
If there is no 103 or 181 mutation associated with resistance to the
class of NNRTIs, then efavirenz (EFV) may be effective. It is critical to know
the protease mutation sites for the selection of a PI.  If there is no mutation
at the 90 codon, saquinavir-SGC may be of some use. Alternatively, if the
indinavir failed because of poor absorption and a lack of an 82 or 84 muta-
tion exists (associated with resistance to RTV or IDV), the combination of
RTV/SQV would be effective. 
If genotyping is not available for this patient, the best blind regimen
would probably be EFV, saquinavir-SGC, RTV and adefovir. Genotyping
would give the prescribing physician comfort in selecting the most appro-
priate proteases. It would also reveal a possibility for a NRTI, which may
make a difference in this salvage regimen. For instance, DDI could be
resalvaged with the use of hydroxyurea. 
Recent data from Zolopa from the 12th International AIDS Conference
demonstrated that in patients who were failing a protease containing regi-
men, that genotypic assays with expert advice were better predictors of a
successful outcome than other clinical or antiretroviral drug history predic-
tors. This was based on a study of 80 patients, 30% of whom became
undetectable using genotype-driven therapy as opposed to 17% of those
in a standard arm.
Unfortunately, there is considerable variability in the quality of available
genotypic assays. I would make sure I was using a reputable company and
base my decisions on the clinical drug history and the genotypic findings.
This patient teaches us much about the natural history of modern anti-
retroviral therapy and the consequences of inadequate therapy at initiation.
Today, newly diagnosed patients have better opportunities for achieving
virological success.
Expert 2:  Joe Bick, M.D.
Chief Medical Officer, 
HIV Treatment, California Medical Facility, Vacaville, CA
Speaker’s Bureau: Agouron, Bristol-Myers Squibb.
Although the past several years have brought encouraging new
treatment options for antiretroviral therapy (ART) naive patients, this man
is more representative of the typical patient encountered in our correc-
tional practices.  Through the early and mid-part of this decade, most
patients were treated with the sequential addition or substitution of one
agent at a time.  We now know that this practice is a sure recipe for the
rapid development of multidrug resistant HIV.
During four years of AZT monotherapy followed by 18 months of D4T
alone, it is likely that significant resistance to both agents developed.
Therefore, switching to the combination of AZT/3TC probably represent-
ed dding a single agent to a resistant regimen, as did adding indinavir
five months later.
In spite of broad cross resistance among protease inhibitors, this
pati  achieved ~ 1 log reduction in his HIV VL by the new regimen.
Unfortunately, his adherence was suboptimal. New adherence data has
shown that missing more than 5% of ART doses (1-2 days worth per
month) leads to a dramatic decline in the percentage of patients who
achieve an undetectable HIV viral load.  (1)  Clearly, this patient did not
hieve that threshold.
Should we simply select three or four agents that the patient hasn't
had before for a salvage regimen?  Data from the genotypic antiretrovi-
ral resistance study (GART) demonstrated that outcomes (as measured
by achieving an undetectable HIV viral load) are significantly better when
reatment decisions are made based upon genotypic analysis and
"expert opinion," as opposed to treatment history alone.  (2) Although
impr vements are needed in resistance assays, they can provide useful
information especially in the setting of heavily pretreated suboptimally
adherent patients.  Thus far, genotyping predicts what will not work bet-
ter than what will.
This patient has not yet received ritonavir, saquinavir, abacavir, or
efavirenz.  However, his prior indinavir and nelfinavir exposure may have
led to mutations that will decrease the efficacy of ritonavir and/or
saquinavir (82, 84, 90).  If his virus is resistant to 3 or more nucleoside
RTIs, it is less likely that abacavir will be effective.  If his nevirapine expo-
sure led to a 103 mutation, it is unlikely that efavirenz will be useful.  For
these reasons, genotyping may be helpful in determining if there is a
chance that previously used agents are still viable treatment options.
Genotyping can cost as much as $600 depending on the laboratory
contract.  On the other hand, triple therapy costs at least $250 per week;
in this patient, at least four drugs may be required costing even more!
R ther than initiating an ineffective regimen and then checking a viral
load 4 to 6 weeks later (>$800-$1,500), the use of a genotypic assay
may be cost effective.
Whatever regimen is chosen, a crucial factor in this patient's eventu-
al treatment success or failure is time spent on education and prepara-
tio .  An effective peer education program can assist in maximizing
adherence.  Attention spent on preparing the patient for and treating any
side effects is also very important.  The next regimen may well be the
only one available for the foreseeable future, so it must be selected with
the utmost care.
M.R. is a 42 year-old male diagnosed with HIV in 1990. He started AZT at that time when his CD4 count was 490 and took AZT monotherapy until
March 1994, when he was changed to D4T monotherapy. In November 1995, his CD4 dropped to 220 and he was switched to AZT plus 3TC. In
April 1996, while on AZT and 3TC, his viral load was 58,000 and his CD4 count was 190. At that time, indinavir 800 TID was added to his therapy.
Within one month, his viral load decreased to 4,200 copies and he tolerated his medications well. By January 1997, after excellent adherence, but
receiving his medication coincident with meals at 6 a.m., noon and 6 p.m., his viral load was 74,000 and his CD4 count was 310. At this time, his
regimen was changed to D4T BID, DDI BID and NFV TID. After 4 weeks, his viral load dropped to 6,800 copies, where it remained for six more
months. However, T cells had risen to 420. The patient had difficulty arriving at the medication line for his midday NFV dose and missed it approx-
imately three times per week.  He intermittently missed his medications because of diarrhea and abdominal cramping. By December 1997, the viral
load had increased to 43,000 and nevirapine was added to his regimen. He has remained on nevirapine and, despite an initial increase in his CD4
count, his viral load is now 168,000 and his CD4 count is down to 260.  What is the next regimen and what would you use?
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1) Paterson et al, 6th Conference on Retroviruses and Opportunistic Infections. Chicago (IL) 1999.  Abstract 92.
2) Baxter et al, 6th Conference on Opportunistic Infections. Chicago (IL) 1999.  Abstract 8.
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Abacavir 
This month we are providing a treatment update on the use of abacavir, a new and most potent NRTI, in corrections. Recent
data using abacavir (ABC, Ziagen®) as part of a protease-sparing regimen has provided early data to suggest its efficacy for
certain groups of individuals infected with HIV.  Despite these findings, the most recent guidelines have not assisted clinicians
on its appropriate use.  In this article, we intend to provide an overview of this new nucleoside analogue and insight into its
appropriate use, possible side effects, and management in the correctional system.
In prospective clinical trials abacavir has been effectively combined with ZDV and 3TC among patients with relatively high CD4
lymphocyte counts (Mean CD4@450). After 48 weeks of therapy and with near similar results as found in triple combinations
using a protease inhibitor, the proportion who achieved a viral load (VL) of <400 copies/mL was 65%. Due to the use of more
sensitive assays (VL < 50 copies/ml), variable results were found among those achieving non-detectable status when stratify-
ing by baseline HIV-1 RNA level (see this month's News Flashes for more information on this assay). Only 28% of those with
baseline VL >100,000 copies/mL achieved successful suppression of viral load below detectable limits. Abacavir's use in
nucleoside-only combinations should probably be reserved for patients with lower baseline viral loads. ABC will also be most
effective when used by patients who have not been heavily pre-treated with nucleoside analogues. Further information on stud-
ies related to this new drug will be included in the May HEPP News.
Thus, the best use of ABC's potency is for nucleoside-naive patients, patients with newly detected antiretroviral failure where
multiple mutations are less likely, or as part of intensification regimens for patients who do not achieve <1000 copies/mL after
4 weeks or <50 copies after 6 months of initiation of therapy. Though official guidelines do not exist for the use of ABC, the fol-
lowing recommendations are based on what we know about the potency of currently recommended antiretrovirals as well as
current pathogenesis information. Three potential clinical scenarios for the use of ABC in combination antiretroviral therapy are
listed in the table below.
Advantages of ABC are that it does not require nor interfere with P450 enzymes for metabolism, it is the only nucleoside analogue that
is not principally cleared renally and is well-tolerated by most patients. With the exception of mild hyperglycemia, ABC has only one
major adverse side effect that must be a concern for correctional physicians and health staff administering ABC. Abacavir
Hypersensitivity Syndrome (AHS) occurs in approximately 3-5% of patients and must be taken very seriously. All definite and most pos-
sible cases of this adverse event occur within the first 6 weeks of therapy. AHS typically begins with nausea, vomiting, myalgias, fever,
and sometimes rash. Symptoms become progressive over several days to weeks. Death has not occurred in patients with this syndrome
who were discontinued within the first week of onset of symptoms. These symptoms are similar to many viral syndromes with a serum-
sickness-like presentation. Unlike a viral syndrome, the AHS will persist beyond 72 hours. This syndrome disappears promptly after dis-
continuation of the medication.
While the syndrome, during its initial presentation has not been associated with significant morbidity or mortality if diagnosed within a
week of onset of symptoms, rechallenge with ABC has resulted in hospitalization and even death secondary to hypotension. Therefore,
among patients who develop a "viral-like" syndrome within the first 6 weeks of therapy, patients must be monitored daily until symptoms
either abate or progress beyond 72-96 hours (See HEPPigram on pg. 4). 
Thus, ABC provides an effective new agent for the management of HIV, however, correctional staff must develop a system for manag-
ing problems and must be adequately taught about the use and consequences of ABC. Hopefully, this review will give more correction-
al staff confidence in its future use.
Clinical Scenarios for the Possible Use of Abacavir (ABC)
Antiretroviral Naive Patients:
a) For patients at any stage of HIV
infection, consider combining with ZDV
or D4T (thymidine analogues) plus
either a potent protease inhibitor or
efavirenz
b)  For patients with non-advanced HIV
(CD4>200 and VL<100,000), consider
using ABC as part of a protease-spar-
ing regimen when combined with:
• ZDV+DDI 
• D4T+DDI
• ZDV+DDC
• ZDV+3TC
• D4T+3TC
Antiretroviral Experienced Patients:
a) Use as part of the first salvage regi-
men when possible
b) Use as part of a salvage regimen
before the viral load rebounds to high
levels when multiple mutations may
develop
c) When possible, obtain a genotypic
assay to determine the number of muta-
tions present to guide ABC's use
Antiretroviral Intensification:
Consider adding ABC to a potent three
drug regimen when early predictors are
present:
a) VL is >1000 copies/mL four weeks
after initiating triple combination therapy
b) VL is >50 copies/mL six months after
initiating triple combination therapy
c) Do not add ABC as a single agent to
a failing regimen
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u February, 1999
New York State Department of Corrections Report Released
The New York AIDS Advisory Council released a report on the New York
State Department of Corrections (NYS DOC). The report was a result of
a project that began ten years ago when the AIDS Advisory Council ini-
tially reported serious deficiencies in prison health services, particularly
for inmates with HIV. At that time, the council recommended immediate
steps for improvement, and suggested that failure to accomplish the
changes within 18 months should result in transfer of authority for inmate
health services to the Department of Health. The February 1999 report by
the New York AIDS Advisory Council again listed many problems with
HIV care in the state's correctional facilities, relating to access to HIV
care, transfer of records and access to HIV testing, counseling, and edu-
cation. To obtain a copy of the report, contact the New York State AIDS
Institute at 518.473.2903.
The Council's report contradicts, in part, a recent report showing a decline
in the number of AIDS deaths within the New York correctional facilities
which is most likely due to providing inmates with increased access to
standard antiretroviral treatments and medications for the prevention of
opportunistic infections. ( MMWR Jan. 8, 1999; 47(51&52) 1115. 
http://www.cdc.gov/epo/mmwr/mmwr.html). 
u March 3, 1999
Ultrasensitive Viral Load Assay Test Approved
The U.S. FDA recently approved Roche's Amplicor Ultrasensitive viral
load test. This assay accurately measures levels of HIV to as low as 50
copies/mL, but is not accurate above 50,000 copies/mL. This means we
have a new lower limit for “undetectable.” Recent studies have indicated
that a viral load below 50 copies/ml is associated with a more complete
and durable viral suppression. Using this test, providers will be able to
monitor more closely the effectiveness of HAART. The cost to laborato-
ries to perform this new ultrasensitive test is the same as for the older
assay. For more information on this test or Roche's patient assistance
program, call 1-888-837-8727.
u March 7 and 15, 1999
Increased Drug Arrests, Climbing Inmate Population
Two articles in the New York Times reported on statistics that the Bureau
of Justice Statistics recently released about prison populations. The
report found that there were 1.8 million inmates incarcerated in the United
States last year (1,277,866 state and Federal inmates, an increase of 4.8
percent; and 592,462 city and county jail inmates, an increase of 4.5 per-
c nt). Experts say increases in prison and jail populations reflect tougher
sentencing laws, longer sentences and tougher parole boards, and imply
that prosecutors and judges are being more stringent.
Drug offenses accounted for the greatest share of the increase in state pris-
oners - almost 30% of crimes committed from 1980 to 1996. Drug-related
crimes are not included in the Federal Bureau of Investigation's calculation
of the national crime rate. Thus, increasing rates of drug-related crimes are
responsible, for the major part, for increases in prison populations. This
information contrasts with popular belief that incarceration rates are
inversely correlated with crime rates.
The overall number of inmates has doubled since 1985, with no signs of
stopping. Rates of HIV infection among inmates are also unlikely to decline
very rapidly in correctional settings, due to increases in the number of indi-
viduals who are arrested for drug-related crimes. See the New York Times
website for the complete text of the articles: www.nytimes.com. For more
u dated statistics, look at the Bureau of Justice Statistics website:
www.ojp.usdoj.gov/bjs/whtsnw2.htm.
News Flashes
9th Annual Clinical Care of the Patient with HIV Infection
April 12 - 13, 1999, Baltimore, MD
This course will provide a state-of-the-art overview of the clinical care of
HIV+ patients for practicing clinicians and other health professionals. 
Sponsored by:Johns Hopkins University, School of Medicine, CME
Contact: Office of CME, Johns Hopkins University, School of Medicine,
tel: (410) 955-2959, fax: (410) 955-0807
email: cmenet@som.adm.jhu.edu. web: www.med.jhu.edu/cme.
HIV Update: Contemporary Issues in Management 
May 2-4, 1999, Boston, MA
Harvard Medical Schools
Beth Israel Deaconess Medical Center
Contact:Professional Meeting Planners
tel: 781.279.9887, 1.800.378.6857
fax: 781.279.9875  email: PMPMeeting@aol.com
International AIDS Society
USA HIV Management Updates
April 12, 1999, San Francisco, CA 
April 21, 1999, Chicago, IL 
May 8, 1999, Cleveland, OH 
This program, now in its seventh year, reviews the most recent develop-
ments in the field of HIV disease pathogenesis and antiretroviral manage-
ment. Expert faculty will speak on timely and clinically relevant issues in
the management of HIV disease. 
Topics include improving the management of HIV disease, HIV pathogen-
esis, antiretroviralas and other selected issues in HIV disease manage-
ment. 
Contact:International AIDS Society--USA
tel: 415.561.6725 
fax: 415.561.6740 
e-mail: cme@iasusa.org
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Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s
Recognition Award.  To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly.  This activity is eligible for CME credit through June
15, 1999.  The estimated time for completion of this activity is one hour and there is no fee for participation in this activity.
1. Which of the following is true about the use of abacavir?
a. it is the most potent nucleoside analogue reverse 
transcriptase inhibitor
b. it is unlikely to be effective as salvage therapy in 
patients who have multiple mutations to zidovudine 
and a single mutation to lamivudine
c. can be an important component of both protease-spar-
ing and protease-containing antiretroviral regimens
d. a and c only
e. a, b and c above
2. The Food and Drug Administration (FDA) has recently
approved use of an ultrasensitive viral load assay that meas-
ures HIV-1 RNA copies from between 50 copies/mL and
50,000 copies/mL.
a. True b. False
3. Which is FALSE about the Abacavir Hypersensitivity
Syndrome?
a. it usually occurs within the first six weeks after 
initiating abacavir
b. usually consists of nausea, vomiting, fevers, 
myalgias and, sometimes rash
c. may be lethal if the medication is not stopped 
within one week during the initial course of abacavir
d. may be lethal if a patient is rechallenged with 
abacavir after the syndrome has developed
e. the syndrome disappears promptly after 
discontinuing the medication
4. Which of the following statements about managing HIV is
incorrect?
a. HIV may take as long as 23 years to eradicate 
using existing antiretroviral therapy
b. genotypic antiretroviral resistance testing is more 
predictive of a virologic success than a standard anti-
retroviral drug history
c. chemokines like Interleukin-2 promote viral 
replication and may expedite eradication of HIV from 
existing reservoirs
d. the standard viral load assay is more useful to use 
to assess prognosis, whereas the new ultrasensitive 
assay is best used to evaluate response to 
antiretroviral therapy
e. abacavir should be used to initiate therapy when 
the viral load is greater than 100,000
5.  A patient who was successfully on an abacavir-containing
regimen for four months was released from prison, however
w  unable to afford medication after release and was on no
antiretroviral therapy when he was reincarcerated two months
later.  Upon return to prison, the patient can safely be restart-
ed on ABC (as part of a potent combination).
a. True b. False
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HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1   
Case Study 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
News Flashes 5  4  3  2  1   5  4  3  2  1   
Save the Dates5  4  3  2  1   5  4  3  2  1   
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPPNews be made more useful to you?
